Healthcare [ 10/13 ] | Medical Devices [ 103/159 ]
NYSE | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 15, 24 | -0.1 Decreased by -300% | -0.1 |
| Nov 2, 23 | -0.24 Decreased by -380% | -0.06 Decreased by -300% |
| Aug 3, 23 | -0.07 Decreased by -133.33% | -0.08 Increased by +12.5% |
| May 4, 23 | -0.33 Decreased by -1.2 K% | -0.14 Decreased by -135.71% |
| Feb 16, 23 | 0.05 Increased by +109.8% | -0.12 Increased by +141.67% |
| Nov 3, 22 | -0.05 Increased by 0% | -0.11 Increased by +54.55% |
| Aug 4, 22 | -0.03 Decreased by -125% | -0.07 Increased by +57.14% |
| May 5, 22 | 0.03 Increased by 0% | -0.12 Increased by +125% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 93.67 M Increased by +17.98% | -3.98 M Decreased by -284.2% | Decreased by -4.24% Decreased by -256.13% |
| Sep 30, 23 | 87.85 M Increased by +14.34% | -9.8 M Increased by +28.53% | Decreased by -11.16% Increased by +37.49% |
| Jun 30, 23 | 89.25 M Increased by +11.09% | -3.38 M Increased by +20.59% | Decreased by -3.79% Increased by +28.52% |
| Mar 31, 23 | 83.23 M Increased by +7.79% | -13.53 M Decreased by -299.29% | Decreased by -16.26% Decreased by -270.43% |
| Dec 31, 22 | 79.4 M Increased by +0.01% | 2.16 M Increased by +110.74% | Increased by +2.72% Increased by +110.74% |
| Sep 30, 22 | 76.84 M Increased by +6.41% | -13.71 M Decreased by -229.59% | Decreased by -17.85% Decreased by -221.78% |
| Jun 30, 22 | 80.34 M Increased by +5.51% | -4.26 M Decreased by -95.55% | Decreased by -5.3% Decreased by -85.34% |
| Mar 31, 22 | 77.21 M Increased by +8.62% | -3.39 M Decreased by -8% | Decreased by -4.39% Increased by +0.57% |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.